ロード中...
No association between use of angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID‐19 in the COvid MEdicaTion (COMET) study
Since the outbreak of SARS‐CoV‐2, also known as COVID‐19, conflicting theories have circulated on the influence of angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) on incidence and clinical course of COVID‐19, but data are scarce. The COvid MEdicaTion (COMET...
保存先:
| 出版年: | Br J Clin Pharmacol |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8014637/ https://ncbi.nlm.nih.gov/pubmed/33507556 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14751 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|